Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 9/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202618 | 1.00 | WEE1 (0.36) | WEE1CHEK1SRCKMT2AMEN1 | |
| SCHEMBL6202615 | 0.78 | WEE1 (0.47) | WEE1CHEK1SRCHSD17B10PIK3CA | |
| SCHEMBL7234231 | 0.77 | KDM4E (0.34) | WEE1CHEK1LMNASMN1; SMN2 | |
| SCHEMBL7234238 | 0.77 | KDM4E (0.34) | WEE1CHEK1LMNASMN1; SMN2 | |
| SCHEMBL7237246 | 0.71 | L3MBTL1 (0.38) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL7245581 | 0.71 | L3MBTL1 (0.38) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL6495062 | 0.71 | WEE1 (0.50) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL6498760 | 0.66 | WEE1 (0.48) | WEE1CHEK1SRCPIK3CAMTOR | |
| Hydrochloric Acid SCHEMBL7249477 | 0.63 | HPGD (0.35) | SRC | |
| Hydrochloric Acid SCHEMBL7249481 | 0.63 | HPGD (0.35) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | WEE1 1065/4885CHEK1 1422/4885SRC 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.